CJC-1295 DAC For Sale — Research Grade

Sourcing High-Purity CJC-1295 DAC for Laboratory Research

In preclinical laboratory settings, sourcing ultra-pure research peptides is vital for generating reproducible, publication-quality data. Investigators seeking CJC-1295 DAC for sale require reagents that adhere to stringent analytical specifications to prevent non-specific cellular responses or assay artifacts caused by sequence truncations, residual solvents, or bacterial endotoxins.

CJC-1295 with Drug Affinity Complex (DAC) is a synthetic 30-amino acid peptide derivative designed to extend the terminal elimination half-life of growth hormone-releasing hormone (GHRH) signaling molecules. When procuring peptides for in vitro cell culture assays or animal tissue repair models, verifying batch-to-batch consistency is essential. PX1 Research manufactures all compounds in cGMP-compliant facilities within the United States, providing detailed analytical validation documentation with every shipment.

Molecular Structure and Drug Affinity Complex (DAC) Chemistry

CJC-1295 DAC is modified from the native GHRH sequence (1-29) through strategic amino acid substitutions and the covalent attachment of a maleimido-propionic acid linker at the C-terminus. The primary structure is represented as D-Ala-L-Asp-L-Ala-L-Ile-L-Phe-L-Thr-L-Gln-L-Ser-L-Tyr-L-Arg-L-Lys-L-Val-L-Leu-L-Ala-L-Gln-L-Leu-L-Ser-L-Ala-L-Arg-L-Lys-L-Leu-L-Leu-L-Gln-L-Asp-L-Ile-L-Leu-L-Ser-L-Arg-Lys(DAC)-NH2.

The inclusion of the Drug Affinity Complex moiety allows the peptide to bioconjugate dynamically to endogenous serum albumin following administration in vivo. Native GHRH and short-acting analogs are rapidly degraded by endopeptidases such as dipeptidyl peptidase IV (DPP-IV) and cleared rapidly via renal clearance. By binding covalently to Lys64 on circulating albumin, the bioconjugated CJC-1295 DAC molecule resists enzymatic cleavage, expanding its systemic circulating half-life in rodent models from minutes to several days.

This structural stability enables long-term kinetic evaluations in growth factor research without requiring continuous intravenous infusions or frequent dosing protocols that can induce mechanical stress responses in animal test subjects.

Mechanism of Action: GHRH Receptor Agonism and Downstream Signaling

CJC-1295 DAC functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRH-R), a Class B G-protein coupled receptor expressed primarily on the somatotroph cells of the anterior pituitary gland. Ligand binding activates the Gs alpha subunit, stimulating transmembrane adenylyl cyclase to convert ATP into cyclic adenosine monophosphate (cAMP).

Elevated intracellular cAMP levels activate protein kinase A (PKA), leading to phosphorylation of the cAMP response element-binding protein (CREB). This signaling cascade drives nuclear transcription of the growth hormone (GH1) gene and triggers intracellular calcium influx via L-type voltage-gated calcium channels, promoting the exocytosis of stored somatotropin granules into physiological circulation.

Unlike short-acting analogs that create acute, transient GH spikes, preclinical models demonstrate that CJC-1295 DAC sustains baseline elevated GH levels while preserving physiological pulse frequency. This sustained baseline secretion subsequently stimulates hepatic gene expression of insulin-like growth factor 1 (IGF-1), a primary mediator of somatic growth, cellular proliferation, and extracellular matrix remodeling in tissue repair research.

Preclinical Research Focus: Tissue Repair and Metabolic Regulation

In vitro and animal models investigating CJC-1295 DAC focus heavily on the secondary and tertiary biological cascades driven by sustained elevated IGF-1 concentrations. Downstream target tissues under active investigation include skeletal muscle, articular cartilage, connective tissue matrices, and myocardial tissue following ischemic events.

Rodent studies exploring skeletal muscle repair indicate that prolonged GHRH-R activation accelerates satellite cell recruitment, myoblast proliferation, and protein synthesis rates following induced mechanical injury. In articular cartilage models, sustained IGF-1 expression mediated by GHRH analogs has been observed to upregulate chondrocyte synthesis of type II collagen and glycosaminoglycans, offering critical insights into articular degeneration and matrix preservation protocols.

Additionally, ongoing investigations within our research library hub detail how GHRH receptor stimulation influences lipid metabolism, cellular autophagic pathways, and nitrogen retention in catabolic animal models. Researchers utilize these findings to elucidate cellular crosstalk between the somatotropic axis and systemic metabolic homoeostasis.

Comparative Analysis: CJC-1295 DAC vs. Non-DAC and Secretagogue Classes

When designing peptide protocols for pituitary signaling studies, investigators often compare GHRH analogs with distinct pharmacokinetic profiles or complementary secretagogue classes. Understanding these operational differences is crucial when selecting compounds from our research peptides directory.

CJC-1295 DAC differs significantly from CJC-1295 without DAC (also known as Modified GRF 1-29). While the non-DAC variant displays a rapid half-life (~30 minutes in rodent models) suitable for mimicking acute physiological GH pulses, the DAC variant provides prolonged receptor engagement lasting up to 6–8 days in preclinical models.

Compared to early-generation GHRH peptides such as Sermorelin, CJC-1295 DAC exhibits superior enzymatic stability against DPP-IV degradation due to D-alanine substitution at position 2. When contrasted with high-affinity GHRH analogs like Tesamorelin, CJC-1295 DAC offers unique bioconjugation properties tailored for extended kinetic research. Furthermore, researchers frequently evaluate GHRH agonists alongside ghrelin mimetics such as Ipamorelin to evaluate dual-receptor synergistic GH release mechanisms in laboratory assays.

Analytical Quality Assurance: HPLC, MS, and Endotoxin Verification

To guarantee valid empirical outcome metrics, laboratory reagents must be free from chemical impurities and biological contaminants. PX1 Research subjects every synthesized lot of CJC-1295 DAC to rigorous quality control protocols executed by independent ISO 17025 accredited laboratories.

Purity is assessed using High-Performance Liquid Chromatography (HPLC) coupled with UV detection. Our standards mandate a minimum chemical purity threshold of >99.0%, ensuring that chromatographic chromatograms display minimal peak broadening, zero secondary isomer peaks, and absence of truncated peptide impurities.

Structural identity is confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS), matching theoretical monoisotopic mass profiles to empirical parent ion peaks. Crucially, because bacterial lipopolysaccharides can induce inflammatory pathways that confound cellular repair research, every lot undergoes chromogenic Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly below <0.01 EU/mg.

Reconstitution Guidelines and Laboratory Storage Protocols

Proper handling and reconstitutive techniques are vital to maintain the structural integrity of lyophilized peptides in laboratory environments. CJC-1295 DAC is supplied as a sterile, lyophilized cake inside sealed borosilicate glass vials with flip-off caps.

For reconstitution, researchers should use sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile deionized research-grade water depending on specific assay requirements. Direct high-pressure liquid stream impingement onto the lyophilized powder should be avoided; instead, allow the diluent to gently flow down the inner glass wall of the vial. Gently swirl or roll the vial until complete dissolution occurs — mechanical agitation or vigorous shaking must be avoided to prevent shear-induced aggregation or peptide denaturation.

Lyophilized CJC-1295 DAC should be stored in desiccated conditions at -20°C for long-term stability (up to 24 months). Following reconstitution, aqueous solutions should be stored at 2°C to 8°C and utilized within 28 days to minimize hydrolytic cleavage or potency loss.

USA Synthesis, Storage, and Fast Same-Day Shipping Infrastructure

PX1 Research maintains complete chain-of-custody control over product synthesis, packaging, and dispatch. All peptide compounds are synthesized within modern facilities located exclusively in the United States, eliminating regulatory unpredictability, international customs delays, and quality degradation associated with overseas imports.

We operate temperature-controlled dispatch facilities strategically situated in California and Arizona. Orders verified before 12:00 PM PST (Monday through Friday) are processed and shipped same-day via expedited courier services.

Temperature-sensitive inventory is stored in sub-zero climate chambers and dispatched with insulated thermal packaging to maintain structural stability during transit. Principal investigators and procurement managers seeking institutional supply or high-volume orders can establish dedicated institutional accounts through our wholesale portal for priority fulfillment schedules and tailored volume pricing.